"LLISA:'Liposome-Linked Immunosorbant Assay' for Detection of HIV Viral Load at Point-of-Care"
“LLISA:用于护理点 HIV 病毒载量检测的‘脂质体联免疫吸附测定’”
基本信息
- 批准号:8721331
- 负责人:
- 金额:$ 21.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-15 至 2016-07-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAddressAffectAfrica South of the SaharaAntibodiesAvidinBedside TestingsBiological AssayBiotinBloodCD4 Positive T LymphocytesCellsChemistryCytolysisDetectionDevelopmentDevicesDiagnosticDiagnostic testsElectric ConductivityElectrodesEnsureGenerationsGoalsHIVHealth PersonnelHome visitationHouse CallHumanIndividualLabelLaboratoriesLifeLinkLiposomesLongevityLymphocyte CountMethodsMicrofluidic MicrochipsMicrofluidicsModelingMonitorPatientsPrincipal InvestigatorPropertyQuality of lifeResourcesSchemeSolutionsStreptavidinSurfaceSymptomsTechniquesTestingTimeVesicular stomatitis Indiana virusViralViral AntibodiesViral Load resultVirionVirusWhole BloodWorkantiretroviral therapybasebiochipcostelectric impedanceinnovationinterdisciplinary collaborationnovelparticlepoint of careportabilityprogramspublic health relevancesuccesstreatment strategyviral detection
项目摘要
DESCRIPTION (provided by applicant): HIV/AIDS affects more than 33 million people throughout the world, and is especially a critical problem in resource-poor regions in sub-Saharan Africa, where 67% of all HIV/AIDS patients live. Antiretroviral therapy (ART) increases the longevity and quality of life for HIV patients, and global efforts have increased the accessibility of such treatment by 30-fold in sub-Saharan Africa between 2003 and 2008. However, the lack of objective diagnostic tests to determine when to start ART and to monitor its success hinders the effective use of treatment. In addition to the counting of CD4+ T Lymphocytes, it is also highly desirable to perform viral load counts at the point-of-care, as both
these parameters are needed for the development of the appropriate treatment strategy. HIV viruses could occur at levels ranging from 10pfu/¿l to thousands of pfu/¿l of whole blood, making it challenging to detect these minute quantities of particles. Current tests include both antibody- based and PCR-based and are not available at point-of-care, especially for resource-limited settings. It should be also pointed out that such devices would of course be extremely valuable also for the developed world, for remote settings, at bedside, or at the doctor's office for a range of applications in detection of viruses. As a solution to these problems presented above, micro-fabricated point-of-care (POC) biochips for HIV/AIDS analysis hold tremendous promise. We propose to develop an integrated device for the electrical detection of HIV viral load at point-of-care. We propose to build on our extensive preliminary work to develop electrically- based sensing methods within micro-fluidic biochips to greatly reduce the operating costs, increase portability, and provide simple-to-use diagnostic kits that can be operated by healthcare workers in remote facilities or during home visits. Our integrated approach is innovative as we will; (i) capture the specific viruses from whole blood, (ii) label these viruses using liposomes tagged with antibodies for the viral particles, (iii) lyse the liposomes by lowerin the electrical conductivity of the medium, and detect the changes in the electrical impedance of the medium in the microfluidic capture chamber. The change in impedance is expected to correlate to the number of virus particles captured. We plan to use VSV-G virus spiked in whole human blood as a model for HIV during this R21 to demonstrate the proof of concept of the novel detection scheme. The interdisciplinary collaboration brings together the expertise of the Co-PIs. We will build on the extensive work in Bashir group (UIUC) on development of microfluidic point-of-care tests that are electrically based, and in Lee Lab (UCI) in microfluidics
and generation of liposomes of controlled size and properties. With the integration of these two sets of expertise, we expect to address the grand challenge of developing point-of-care viral load assays.
描述(申请人提供):艾滋病毒/艾滋病影响着全世界3300多万人,在撒哈拉以南非洲资源贫乏的地区尤其严重,那里居住着67%的艾滋病毒/艾滋病患者。抗逆转录病毒疗法(ART)提高了艾滋病毒患者的寿命和生活质量,2003至2008年间,全球努力使撒哈拉以南非洲地区获得这种治疗的机会增加了30倍。然而,缺乏客观的诊断测试来确定何时开始抗逆转录病毒治疗并监测其成功与否,阻碍了有效治疗的使用。除了对CD4+T淋巴细胞进行计数外,在护理点进行病毒载量计数也是非常必要的,因为两者
这些参数对于制定适当的治疗策略是必要的。HIV病毒可能发生在从10pfu/?L到数千pfu/?L的全血中,这给检测这些微量的颗粒物带来了挑战。目前的检测既包括基于抗体的检测,也包括基于聚合酶链式反应的检测,并且不能在护理地点使用,特别是在资源有限的情况下。还应该指出的是,这种设备对于发达国家来说当然也是非常有价值的,对于远程设置、床边或医生办公室中检测病毒的一系列应用来说。作为上述这些问题的解决方案,用于艾滋病毒/艾滋病分析的微型制造的护理点(POC)生物芯片具有巨大的前景。我们建议开发一种集成设备,用于在护理地点对艾滋病毒病毒载量进行电子检测。我们建议在我们广泛的前期工作的基础上,在微流控生物芯片内开发基于电子的传感方法,以极大地降低运营成本,增加便携性,并提供简单易用的诊断试剂盒,供医护人员在偏远设施或家访期间操作。我们的集成方法是创新的,我们将:(I)从全血中捕获特定的病毒,(Ii)使用标记有病毒颗粒抗体的脂质体标记这些病毒,(Iii)通过降低介质的电导率来裂解脂质体,并检测微流控捕捉室中介质的电阻抗变化。阻抗的变化预计与捕获的病毒颗粒的数量有关。我们计划在R21期间使用在全人类血液中添加的VSV-G病毒作为HIV的模型,以演示新检测方案的概念证明。这种跨学科协作汇聚了各合作伙伴的专门知识。我们将在Bashir Group(UIUC)和Lee Lab(UCI)在微流体方面的广泛工作的基础上开发基于电子的微流体护理点测试
以及大小和性质可控的脂质体的产生。随着这两套专业知识的整合,我们希望解决开发护理点式病毒载量分析的巨大挑战。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rashid Bashir其他文献
Rashid Bashir的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rashid Bashir', 18)}}的其他基金
Point-of-Care Microfluidic Biochip for Biomarkers Monitoring for Contributing in Early Sepsis Diagnosis
用于生物标志物监测的护理点微流控生物芯片有助于早期脓毒症诊断
- 批准号:
10673974 - 财政年份:2021
- 资助金额:
$ 21.06万 - 项目类别:
Point-of-Care Microfluidic Biochip for Biomarkers Monitoring for Contributing in Early Sepsis Diagnosis
用于生物标志物监测的护理点微流控生物芯片有助于早期脓毒症诊断
- 批准号:
10462484 - 财政年份:2021
- 资助金额:
$ 21.06万 - 项目类别:
Smartphone-linked system for diagnosis and epidemiological reporting of pathogens at the point of care
智能手机连接系统,用于在护理点诊断和流行病学报告病原体
- 批准号:
10462690 - 财政年份:2019
- 资助金额:
$ 21.06万 - 项目类别:
High accuracy optical growth assay of 3D cellular systems
3D 细胞系统的高精度光学生长测定
- 批准号:
10330571 - 财政年份:2019
- 资助金额:
$ 21.06万 - 项目类别:
Smartphone-linked system for diagnosis and epidemiological reporting of pathogens at the point of care
智能手机连接系统,用于在护理点诊断和流行病学报告病原体
- 批准号:
10241489 - 财政年份:2019
- 资助金额:
$ 21.06万 - 项目类别:
Atomically-thin diode integrated into a nanopore DNA Sensor
集成到纳米孔 DNA 传感器中的原子薄二极管
- 批准号:
9808985 - 财政年份:2019
- 资助金额:
$ 21.06万 - 项目类别:
Multiplexed Pathogen Detection from Whole Blood for Rapid Detection of Sepsis
全血多重病原体检测可快速检测脓毒症
- 批准号:
9809870 - 财政年份:2019
- 资助金额:
$ 21.06万 - 项目类别:
LLISA: ???Liposome-Linked Immunosorbant Assay??? for Detection of HIV Viral Load
LLISA:???脂质体连接免疫吸附测定???
- 批准号:
8514874 - 财政年份:2013
- 资助金额:
$ 21.06万 - 项目类别:
Measurements of BPDE-DNA adducts by solid state nonopore and deep sequencing (PQ
通过固态非孔和深度测序 (PQ
- 批准号:
8534070 - 财政年份:2012
- 资助金额:
$ 21.06万 - 项目类别:
Measurements of BPDE-DNA adducts by solid state nonopore & deep sequencing (PQ3
通过固态非孔测量 BPDE-DNA 加合物
- 批准号:
8384743 - 财政年份:2012
- 资助金额:
$ 21.06万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 21.06万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 21.06万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 21.06万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 21.06万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 21.06万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 21.06万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 21.06万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 21.06万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 21.06万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 21.06万 - 项目类别:
Research Grant














{{item.name}}会员




